WallStreetZenWallStreetZen

NASDAQ: NXTC
Nextcure Inc Stock

$1.74+0.06 (+3.57%)
Updated Jun 2, 2023
NXTC Price
$1.74
Fair Value Price
$2.70
Market Cap
$48.43M
52 Week Low
$1.16
52 Week High
$5.27
P/E
-0.69x
P/B
0.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$70.23M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$53M
Beta
0.96
Next Earnings
Aug 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A

NXTC Overview

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NXTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NXTC ($1.74) is undervalued by 35.55% relative to our estimate of its Fair Value price of $2.70 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NXTC ($1.74) is significantly undervalued by 35.55% relative to our estimate of its Fair Value price of $2.70 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NXTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NXTC due diligence checks available for Premium users.

Be the first to know about important NXTC news, forecast changes, insider trades & much more!

NXTC News

Valuation

NXTC fair value

Fair Value of NXTC stock based on Discounted Cash Flow (DCF)
Price
$1.74
Fair Value
$2.70
Undervalued by
35.55%
NXTC ($1.74) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NXTC ($1.74) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NXTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NXTC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.69x
Industry
11.51x
Market
52.69x

NXTC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
5.2x
NXTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NXTC's financial health

Profit margin

Revenue
$0.0
Net Income
-$16.1M
Profit Margin
0%
NXTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$167.8M
Liabilities
$13.6M
Debt to equity
0.09
NXTC's short-term assets ($148.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NXTC's short-term assets ($148.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NXTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.8M
Investing
$18.1M
Financing
$0.0
NXTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NXTC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NXTC$48.43M+3.76%-0.69x0.31x
SLS$48.47M+1.18%-1.04x3.68x
ENLV$48.73M+4.13%-1.57x0.86x
EIGR$48.73M-1.79%-0.50x1.38x
AVRO$48.96M+3.74%-0.48x0.92x

Nextcure Stock FAQ

What is Nextcure's quote symbol?

(NASDAQ: NXTC) Nextcure trades on the NASDAQ under the ticker symbol NXTC. Nextcure stock quotes can also be displayed as NASDAQ: NXTC.

If you're new to stock investing, here's how to buy Nextcure stock.

What is the 52 week high and low for Nextcure (NASDAQ: NXTC)?

(NASDAQ: NXTC) Nextcure's 52-week high was $5.27, and its 52-week low was $1.16. It is currently -66.98% from its 52-week high and 50% from its 52-week low.

How much is Nextcure stock worth today?

(NASDAQ: NXTC) Nextcure currently has 27,834,911 outstanding shares. With Nextcure stock trading at $1.74 per share, the total value of Nextcure stock (market capitalization) is $48.43M.

Nextcure stock was originally listed at a price of $19.90 in May 9, 2019. If you had invested in Nextcure stock at $19.90, your return over the last 4 years would have been -91.26%, for an annualized return of -45.62% (not including any dividends or dividend reinvestments).

How much is Nextcure's stock price per share?

(NASDAQ: NXTC) Nextcure stock price per share is $1.74 today (as of Jun 2, 2023).

What is Nextcure's Market Cap?

(NASDAQ: NXTC) Nextcure's market cap is $48.43M, as of Jun 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nextcure's market cap is calculated by multiplying NXTC's current stock price of $1.74 by NXTC's total outstanding shares of 27,834,911.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.